Medical Device Works, a pioneer of organ isolation technologies, has developed a breakthrough high-tech medical device to be added to the arsenal against cancer: PILP.
PILP allows for isolating an organ by controlling its blood flow and for performing repeated chemotherapy administration in a minimally invasive manner directly to the tumor. These courses of chemotherapy are administered at very high concentrations to the organ, without inducing side effects of chemotherapy common after other liver cancer treatments.
By targeting only the diseased organ, increasing the concentration up to 20 times and sparing healthy tissue, our catheters create a closed circuit and bring a unique solution to the lack of effectiveness of chemotherapy against solid cancers (liver, lung , pancreas): they help deliver a drug proven to be effective for the given tumor at a very high concentration directly to the organ.
The first application of our technology, the result of many years of R&D and protected by strong worldwide patents, targets liver cancer. The stakes are high: every year, more than 700,000 people are diagnosed with liver cancer. Nearly 130,000 of these cases have inoperable cancer and could potentially be treated by our device. The market, estimated at about 2 billion euros, is considerable. This market estimate does not include development potential in the treatment of other sites of cancerous tumors with high mortality (e.g. lung, pancreas), against which our system could also apply.
Our ambition is to become an international contributor to interventional oncology, a new promising market comparable to the revolution experienced in interventional cardiology in the last 15 years.
Market capitalization (07-Dec-2016)
Closing share price (07-Dec-2016)